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Introduction
The 22nd Annual San Antonio Breast Cancer Symposium
attracted over 3000 registrants, making it one of the
largest regular conferences devoted to breast cancer
research and treatment. In keeping with the wishes of its
founder, the late William McGuire, there were no parallel
sessions. Instead, there was a packed schedule of plenary
speakers, general sessions and minisymposia, which all
delegates were expected to attend and, more importantly,
to participate in. This year the WL McGuire Memorial
Lecture was given by Charles Coltman (University of Texas
Health Science Center, San Antonio, TX, USA), who paid
tribute to Bill McGuire’s legacy of rigorously conducted
clinical and translational research. The other plenary speak-
ers were Walter Willett (Harvard School of Public Health,
Boston, MA, USA), Martin Cheever (Corixa, Seattle, WA,
USA), Richard Elledge (Baylor College of Medicine,
Houston, TX, USA), Joseph Costantino (NSABP Biostatis-
tics Center and University of Pittsburgh, Pittsburgh, PA,
USA) and Marc Lippman (Georgetown University School
of Medicine, Washington, WA, USA), whose topics ranged
from the nutritional and behavioural causes of breast
cancer through immunotherapy to risk assessment and the
epidermal growth factor receptor (EGFR) superfamily.
Areas such as micrometastases, premalignant and preinva-
sive disease, and high-dose chemotherapy were covered in
minisymposia, whereas the general sessions comprised
short communications of general interest, late breaking
results or the results of particularly interesting or important
clinical trials. Finally, there were nearly 500 posters spread
over five early morning or evening sessions.
Breast development and premalignant disease
Barry Gusterson (Institute of Cancer Research, London,
UK) outlined the current understanding of stem cells and
the biology of human breast development. The location of
stem cells in the human breast remains uncertain, but
extrapolation of the results of studies on the mouse
mammary gland suggests that 1 in 1000 cells can be
classed as progenitors and must be regarded as targets
for neoplastic transformation. Ablation of stem cells is an
important goal of breast cancer prevention and treatment
strategies, and it was good to hear that this area has been
prioritized for funding by the US National Cancer Institute.
The mouse mammary gland is becoming increasingly
important as a model in which the effects of altering single
genes on the biology of breast and breast tumour develop-
ment can be studied. Jeff Rosen (Baylor College of Medi-
cine, Houston, USA) described experiments that showed
important interactions between the BRCA1 and TP53
tumour suppressor genes in breast tumour formation. Con-
ditional deletion of the Brca1 gene from the mouse
mammary gland resulted in developmental abnormalities
and, eventually, the development of p53-null tumours.
Crossing the conditional Brca1-knockout mice into a p53-
null background greatly accelerated the formation of
tumours that were strongly reminiscent of human ductal
carcinoma in situ (DCIS). Other knockout studies
described by Jeff Rosen have shown a key role for the tran-
scription factor C/EBPb in mouse mammary gland differen-
tiation. The mammary glands from mice lacking c/ebpb
showed abnormalities in ductal morphogenesis and were
unable to lactate. In another experiment, the introduction of
a dominant-negative C/EBPb transgene, liver inhibitory
protein, enhanced proliferation and the formation of pre-
neoplastic lesions. Interestingly, liver inhibitory protein was
overexpressed in 23% of human invasive ductal carcino-
mas, in which it was associated with a poorer prognosis.
Oestrogen receptor biology and biochemistry
The oestrogen receptor (ER) is a major target of current
breast cancer prevention and treatment strategies, but ourBreast Cancer Research    Vol 2 No 2 Clarke and Anderson
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understanding of this receptor is still expanding. Work by
Robert Clarke (Christie Hospital NHS Trust, Manchester,
UK) that showed that ER-containing epithelial cells
express p27KIP1 and are growth-arrested suggests that
these cells are a differentiated population that may control
the activity of adjacent proliferation-competent cells via
paracrine and/or juxtacrine factors. A novel ER coregula-
tory molecule, HET/SAF-B, described by Steffi Oesterrich
(University of Texas Health Science Center, San Antonio,
TX, USA) maps to human chromosome 19p13, an area
frequently affected by loss of heterozygosity in human
breast tumours. This new coregulator recognizes the ER
when bound to tamoxifen and enhances antioestrogenic
activity of this drug, and its expression is reduced in cul-
tured breast cancer cells resistant to the inhibitory effects
of antioestrogens. Finally, Adrian Lee (University of Texas
Health Science Center, San Antonio, TX, USA) showed
the complete interdependence of the insulin-like growth
factor receptor and the ER signalling pathways in cultured
human breast cancer cells, suggesting alternative targets
for antitumour therapies.
Molecular analyses
Recently, important new methods of analyzing large
numbers of molecular and chromosomal changes in small
samples have been developed and a number of groups
reported preliminary results from their use of such
methods. For example, DM Euhus (University of Texas
Southwestern Medical Center, Dallas, TX, USA)
described an increased number of changes in microsatel-
lite sequences in fine-needle aspirate samples of normal
tissue taken from women at very high risk for breast
cancer. FM Waldman (University of California, San Fran-
cisco, CA, USA) used comparative genome hybridization
(CGH) to show that nearly all DCIS recurrences were
closely related to their primary lesions. The use of comple-
mentary DNA microarrays to find changes in gene expres-
sion common to hereditary but not sporadic tumours was
reported by EMJJ Berns (Josephine Nefkins Institute, Rot-
terdam, The Netherlands). Another use of microarray tech-
nology was demonstrated by L Assersohn (Royal Marsden
Hospital, London, UK), who used it to examine fine-needle
aspirates taken from tumours before, during and after
presurgical tamoxifen treatment. In all, the expression of
190 genes was changed significantly by antioestrogen
treatment, but several interesting clusters of genes
emerged, some of which were common to all tumours. RA
Baldocchi (University of California at San Francisco
Cancer Center, San Francisco, CA, USA) described an
oligonucleotide array-based CGH technique to assess
gene loss or amplification. In this technique amplified
tumour complementary DNA is hybridized to an array of
oligonucleotides corresponding to sequences from the
genes of interest. Thus, information regarding genetic loss
or amplification is obtained and, it is claimed, the tech-
nique has greater resolution and is more quantitative than
existing CGH methods based on hybridization to
metaphase chromosome spreads. Methodologies such as
this and the others described above have great potential
in the study of human tissues (both normal and malignant),
because often only a very small sample is required and the
analysis of hundreds if not thousands of genes is possible. 
New chemotherapeutic strategies
As ever, new strategies for treating advanced breast
cancer and new targets for preventive or adjuvant treat-
ment are needed, and an entire minisymposium was
devoted to the subject of high-dose chemotherapy. The
‘take home’ message from this session was that high-dose
regimens with or without blood stem-cell support offer no
significant improvements in overall or relapse-free survival
compared with more conventional schedules, and were
associated with more serious adverse side effects.
Several presentations confirmed the clinical efficacy of the
Herceptin (Genentech, San Francisco, CA, USA) antibody
against the c-erbB2/HER2 cell-surface receptor when
administered in combination with cytotoxics such as pacli-
taxel or vinorelbine. The HER2 receptor was also the
target of immunotherapy strategies described by Martin
Cheever (Corixa, Seattle, WA, USA). HER2 may not be an
ideal antigen, however, so differential display was used to
identify two new antigens, one or the other of which was
overexpressed in 90% of breast tumours examined.
Inhibitors of receptor tyrosine kinases such as the EGFR
or HER2 receptors have been developed recently. Kai
Chan (University Hospital of South Manchester, Manches-
ter, UK) showed that the compound Iressa (AstraZeneca,
Macclesfield, Cheshire, UK) decreased the proliferative
activity of normal human breast epithelium and DCIS when
implanted into athymic nude mice, suggesting that this
class of compounds might have a role in the management
of preinvasive as well as advanced disease. In his plenary
lecture, Marc Lippman (Georgetown University School of
Medicine, Washington, WA, USA) revealed that a new
target for receptor tyrosine kinase inhibition might be a
variant of the EGFR, EGFRvIII, which appears to be over-
expressed in a large proportion of human breast tumours.
New prognostic markers
An important aspect of managing breast cancer is predict-
ing both the likely course of the disease and the likely
response to specific treatments. Promising new prognos-
tic markers include p27KIP1, increased levels of which are
associated with longer survival in young women with
breast cancer. Conversely, low levels of a bcl-2 binding
protein BAG-1, an antiapoptotic protein, are associated
with a better outlook in early breast cancer. Bivariate flow
cytometric analysis of cellular cytokeratin and DNA
content improves detection of hypodiploidy and
tetraploidy, both of which are associated with poorer prog-
nosis. Cytokeratin immunohistochemistry was used to
show that micrometastases in bone marrow were indepen-3
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dent markers of poor prognosis, as were micrometastases
in lymph nodes removed from early-stage breast cancer
patients. Several papers reported preliminary results of
sentinel node mapping as an alternative to full axillary dis-
section in suitable patients, although the clinical useful-
ness of such techniques remains to be established.
Prevention and prediction of breast cancer risk
It seems likely that the most significant advances will be
made in the areas of prevention and in prediction of breast
cancer risk. Walter Willett (Harvard School of Public
Health, Boston, MA, USA) reported that women with the
lowest risk of breast cancer are those who have had an
early first pregnancy, who have maintained the same body
weight since they were 18 years old, who have a Mediter-
ranean diet, who do not drink and who do not use
hormone replacement therapy. The inter-relationships
between these factors are complex, but a better under-
standing should suggest new ways of preventing breast
cancer. Accurate prediction of risk is also important for
women with a family history of breast cancer and Richard
Elledge (Baylor College of Medicine, Houston, TX, USA)
presented data that revise estimates of the penetrance of
the  BRCA1 breast cancer susceptibility gene. It now
seems likely that the incidence of breast cancer before the
age of 70 years in BRCA1 mutation carriers is 56%, with
a range of 40–85% and a median age of 40–45 years at
onset. This contrasts with the estimate of 87% described
in earlier studies. Estimates of the incidence of ovarian
cancer in these women may also have to be revised down-
wards and Elledge attributes the discrepancy to ascertain-
ment bias in the earlier studies, to genotype influences,
modifying factors and plain old chance. These revised
figures should allow more appropriate counselling and
application of risk management strategies, however, such
as prophylactic mastectomy in women with a family history
of breast cancer.
Conclusion
The 22nd Annual San Antonio Breast Cancer Symposium
achieved its aim of promoting discussion and interactions
between all sections of the breast cancer research and
treatment community.
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